Skip to main content
Explore URMC

Daniel J. Lachant, D.O.

Contact Information

Phone Numbers

Appointment: (585) 486-0147

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



I primarily treat patients with pulmonary hypertension, heart failure, and pulmonary embolus (blood clots in the lung). My goal is to improve and provide access to care for patients with pulmonary vascular disease across New York and central Pennsylvania. We are a nationally accredited PHA (Pulmonary Hypertension Association) Comprehensive Care Center with an outpatient clinic and inpatient service at Strong Memorial Hospital. The URMC Pulmonary Hypertension group consists of my partner and mentor Jim White, MD,PhD; clinical/research nurse (Andrew Mintz); two research technicians (Deborah Haight and Jackie Bruno); a full time administrator (Monique Johnson); a research study coordinator (Michael Lachant) and a post-doctoral research associate (Allison Light PhD). We are involved with multiple pharmaceutical clinical trials, translational research, and laboratory research. Our pulmonary hypertension group has collaborated with the Pulmonary Hypertension Association to create a how to safely exercise videos series.

Professional Background

I grew up in Ohio before moving to Philadelphia where I obtained my undergraduate degree (Biology) and was a collegiate rower at St. Joseph's University. I obtained my medical degree at the Philadelphia College Osteo Medicine. Afterwards I came to the University of Rochester for my internal medicine training and stayed for my Pulmonary and Critical Care fellowship. I am now apart of the URMC Pulmonary Hypertension group that is a nationally accredited PHA Comprehensive Care Center.


I have two areas of active research trying to personalize pulmonary vascular disease.

The first is using digital technology to measure changes in heart rate during the 6-minute walk test (submaximal exercise). We have found this measurement (Cardiac Effort) to be more reproducible than walk distance alone and correlates extremely well with right ventricular function. We are exploring other outcomes associated with this measurement. We are also looking at changes in actigraphy as a marker of treatment response. The other area of research is evaluating baseline and changes in vascular and coagulation parameters to better phenotype and characterize treatment strategies.



  • Critical Care Medicine - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Pulmonary Disease - American Board of Internal Medicine


DO | Philadelphia College of Osteopathic Medicine

Post-doctoral Training & Residency

07/01/2014 - 06/30/2017
Fellowship in Pulmonary/Critical Care at University of Rochester Medical Center

07/01/2012 - 06/30/2014
Residency in Internal Medicine at University of Rochester

07/01/2011 - 06/30/2012
Internship in Internal Medicine at University of Rochester

VIEW ALL expand_more


Journal Articles

Arevalo C, White RJ, Le T, Lachant D. "Vasodilator use in precapillary pulmonary hypertension with end stage kidney disease: A single center experience." Respiratory medicine.. 2021 Sep 4; 188:106596. Epub 2021 Sep 04.

Roto D, Lachant NA, James White R, Lachant DJ. "Resting heart rate as a surrogate for improvement in intermediate risk pulmonary embolus patients?" Respiratory medicine.. 2021 Aug 17; 187:106578. Epub 2021 Aug 17.

Lachant D, Roto D, Rappaport S, Prasad P, Lachant N, White RJ. "Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza." Thrombosis research.. 2021 Jul 3; 205:40-43. Epub 2021 Jul 03.